New Therapies and Immunological Findings in Nasopharyngeal Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 9564
Special Issue Editors
Interests: nasopharyngeal carcinoma, tumor microenvironment; adoptive T cell therapy
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue on “New Therapies and Immunological Findings in Nasopharyngeal Carcinoma”. Endemic nasopharyngeal carcinoma is associated with Epstein–Barr virus (EBV) and the reports of abundant lymphocyte infiltration in the tumor strongly suggest that it is an immune-elated cancer. There is a long history of clinical trials using immunotherapy in NPC. Various attempts at targeting the EBV, including the EBV vaccine and EBV-specific T cells therapy, had only limited success. While immunotherapy using checkpoint inhibitors and CAR-T cell therapy had firmly been established as a standard of care in other cancers, the advances in immunotherapy for NPC have lagged behind. Single-agent PD-1 inhibitors have limited efficacy in chemotherapy-resistant disease. While combined treatment with chemotherapy and PD-1 inhibitors was shown to improve responses and disease-free survival in first-line settings of metastatic disease, there is no biomarker that can predict patient responses to treatment. Thus, there is an urgent need to review our current knowledge on the immunology and immunotherapy of NPC and to search for new directions to improve the current therapeutics.
This Special Issue aims to review our knowledge on immune biology and to report new immune therapeutics for NPC. The scope will include revisiting the role of EBV, identifying potential pathways that cause T cell exhaustion and immune evasion, looking for new targets for immune therapy and immune modulation and identification of biomarkers for predicting response to checkpoint inhibitors or cellular therapy.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: studies on the tumor microenvironment and systemic immunology, reports on neoantigens and novel targets for immunotherapy. We also call for reports on pre-clinical studies on new immunotherapy. Reports from early phase clinical trials and their correlative laboratory findings, especially on predictive biomarkers, are most welcome.
We look forward to receiving your contributions.
Prof. Dr. Dora Kwong
Dr. Darren Wan Teck Lim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EBV
- tumor microenvironment
- neoantigens
- checkpoint inhibitors
- cellular immunotherapy
- vaccine
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.